Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
de Clercq
E
E
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use; D012194:RNA-Directed DNA Polymerase / Q000187:drug effects* / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D009705:Nucleosides; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase